We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$76.3M
AUM Growth
-$26.5M
Cap. Flow
-$21M
Cap. Flow %
-27.59%
Top 10 Hldgs %
86.7%
Holding
43
New
13
Increased
–
Reduced
2
Closed
25

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$10.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$9.86M
3
CYTK icon
Cytokinetics
CYTK
+$9.11M
4
BLU
BELLUS Health Inc.
BLU
+$8.78M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$8.07M

Top Sells

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$8.58M
2
WHWK
Whitehawk Therapeutics
WHWK
+$8.12M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.56M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.22M
5
ALLK
Allakos
ALLK
+$5.24M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$9.79M 12.83%
+487,631
New +$10.5M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.6B
$9.55M 12.52%
+266,961
New +$9.86M
BLU
3
DELISTED
BELLUS Health Inc.
BLU
$8.15M 10.68%
+1,131,827
New +$8.78M
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$7.86M 10.3%
+223,382
New +$9.11M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.8B
$7.17M 9.4%
+29,614
New +$8.07M
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.21M 8.14%
+255,310
New +$5.59M
MRUS
7
DELISTED
Merus
MRUS
$5.08M 6.66%
+275,970
New +$4.81M
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$4.9M 6.42%
47,651
– –
JSPR icon
9
Jasper Therapeutics
JSPR
$29.4M
$4.56M 5.97%
+251,723
New +$4.65M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.82B
$2.87M 3.76%
+20,830
New +$2.7M
CTIC
11
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.31M 3.03%
+550,000
New +$2.85M
MDVL
12
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$1.69M 2.21%
117,898
– –
MDXH icon
13
MDxHealth
MDXH
$21.7M
$1.62M 2.12%
+500,000
New +$2.28M
MLTX icon
14
MoonLake Immunotherapeutics
MLTX
$1.64B
$1.56M 2.04%
+72,850
New +$1.22M
RPID icon
15
Rapid Micro Biosystems
RPID
$103M
$917K 1.2%
699,664
– –
EPIX
16
DELISTED
ESSA Pharma
EPIX
$703K 0.92%
236,583
-574,972
-71% -$1.69M
KNTE
17
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$684K 0.9%
+109,393
New +$666K
SYRS
18
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$665K 0.87%
249,126
-619,277
-71% -$2.4M
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-474,741
Closed -$7.56M
ALKS icon
20
Alkermes
ALKS
$8.79B
– –
-142,002
Closed -$3.71M
ALLK
21
DELISTED
Allakos
ALLK
– –
-622,364
Closed -$5.24M
AMRN
22
Amarin Corp
AMRN
$292M
– –
-186,543
Closed -$4.51M
AVIR icon
23
Atea Pharmaceuticals
AVIR
$390M
– –
-962,694
Closed -$4.63M
BHVN icon
24
Biohaven
BHVN
$2.32B
– –
-179,085
Closed -$2.49M
CRIS icon
25
Curis
CRIS
$9.02M
– –
-2,068
Closed -$455K
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q1 2023 Portfolio in Review

As of Q1 2023, Ally Bridge Group held 43 positions worth $76.3M, down 26% from $103M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Ally Bridge Group withdrew a net $21M in Q1 2023, closing 25 positions and reducing 2 holdings. Its most notable exit was Ultragenyx Pharmaceutical, an estimated $8.58M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Ally Bridge Group opened a new position in Verona Pharma worth $9.79M.

  • Ally Bridge Group's largest Q1 2023 buy was Verona Pharma: 487,631 shares worth $9.79M.
  • Ally Bridge Group's biggest Q1 2023 reduction was Syros Pharmaceuticals, Inc. Common Stock, cutting an estimated $2.4M.
  • Ally Bridge Group fully exited Ultragenyx Pharmaceutical in Q1 2023, selling an estimated $8.58M.
  • Ally Bridge Group's ten largest holdings make up 87% of its $76.3M portfolio in Q1 2023.
  • Ally Bridge Group opened 13 new positions and closed 25 in Q1 2023.
  • Ally Bridge Group's portfolio value fell 26% quarter-over-quarter to $76.3M.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.